283 related articles for article (PubMed ID: 16952304)
1. CCR4 as a novel molecular target for immunotherapy of cancer.
Ishida T; Ueda R
Cancer Sci; 2006 Nov; 97(11):1139-46. PubMed ID: 16952304
[TBL] [Abstract][Full Text] [Related]
2. Defucosylated anti-CCR4 monoclonal antibody exercises potent ADCC-mediated antitumor effect in the novel tumor-bearing humanized NOD/Shi-scid, IL-2Rgamma(null) mouse model.
Ito A; Ishida T; Yano H; Inagaki A; Suzuki S; Sato F; Takino H; Mori F; Ri M; Kusumoto S; Komatsu H; Iida S; Inagaki H; Ueda R
Cancer Immunol Immunother; 2009 Aug; 58(8):1195-206. PubMed ID: 19048251
[TBL] [Abstract][Full Text] [Related]
3. Macrophage-derived chemokine is a functional ligand for the CC chemokine receptor 4.
Imai T; Chantry D; Raport CJ; Wood CL; Nishimura M; Godiska R; Yoshie O; Gray PW
J Biol Chem; 1998 Jan; 273(3):1764-8. PubMed ID: 9430724
[TBL] [Abstract][Full Text] [Related]
4. Tumors establish resistance to immunotherapy by regulating T
Marshall LA; Marubayashi S; Jorapur A; Jacobson S; Zibinsky M; Robles O; Hu DX; Jackson JJ; Pookot D; Sanchez J; Brovarney M; Wadsworth A; Chian D; Wustrow D; Kassner PD; Cutler G; Wong B; Brockstedt DG; Talay O
J Immunother Cancer; 2020 Nov; 8(2):. PubMed ID: 33243932
[TBL] [Abstract][Full Text] [Related]
5. Production of thymus and activation-regulated chemokine and macrophage-derived chemokine by CCR4+ adult T-cell leukemia cells.
Shimauchi T; Imai S; Hino R; Tokura Y
Clin Cancer Res; 2005 Mar; 11(6):2427-35. PubMed ID: 15788694
[TBL] [Abstract][Full Text] [Related]
6. Increased CCR4 expression in cutaneous T cell lymphoma.
Ferenczi K; Fuhlbrigge RC; Pinkus J; Pinkus GS; Kupper TS
J Invest Dermatol; 2002 Dec; 119(6):1405-10. PubMed ID: 12485447
[TBL] [Abstract][Full Text] [Related]
7. CCL17 acts as an antitumor chemokine in micromilieu-driven immune skewing.
Li Y; Cao H; Jiang Z; Yan K; Shi J; Wang S; Wang F; Wang W; Li X; Sun N; Liu L; Chen L; Chen Y; Guo R; Song Y
Int Immunopharmacol; 2023 May; 118():110078. PubMed ID: 37001380
[TBL] [Abstract][Full Text] [Related]
8. [Anti-CCR4 mAb and regulatory T cells].
Kurose K; Ohue Y; Oka M
Gan To Kagaku Ryoho; 2013 Sep; 40(9):1150-5. PubMed ID: 24047773
[TBL] [Abstract][Full Text] [Related]
9. Immunopathogenesis of lymphoma: focus on CCR4.
Ishida T; Ueda R
Cancer Sci; 2011 Jan; 102(1):44-50. PubMed ID: 21044233
[TBL] [Abstract][Full Text] [Related]
10. Mogamulizumab and the treatment of CCR4-positive T-cell lymphomas.
Remer M; Al-Shamkhani A; Glennie M; Johnson P
Immunotherapy; 2014; 6(11):1187-206. PubMed ID: 25496334
[TBL] [Abstract][Full Text] [Related]
11. Clinical Application of Anti-CCR4 Monoclonal Antibody.
Ueda R
Oncology; 2015; 89 Suppl 1():16-21. PubMed ID: 26550987
[TBL] [Abstract][Full Text] [Related]
12. Unique chemotactic response profile and specific expression of chemokine receptors CCR4 and CCR8 by CD4(+)CD25(+) regulatory T cells.
Iellem A; Mariani M; Lang R; Recalde H; Panina-Bordignon P; Sinigaglia F; D'Ambrosio D
J Exp Med; 2001 Sep; 194(6):847-53. PubMed ID: 11560999
[TBL] [Abstract][Full Text] [Related]
13. The CC chemokine receptor 4 as a novel specific molecular target for immunotherapy in adult T-Cell leukemia/lymphoma.
Ishida T; Iida S; Akatsuka Y; Ishii T; Miyazaki M; Komatsu H; Inagaki H; Okada N; Fujita T; Shitara K; Akinaga S; Takahashi T; Utsunomiya A; Ueda R
Clin Cancer Res; 2004 Nov; 10(22):7529-39. PubMed ID: 15569983
[TBL] [Abstract][Full Text] [Related]
14. Frequent expression of CCR4 in adult T-cell leukemia and human T-cell leukemia virus type 1-transformed T cells.
Yoshie O; Fujisawa R; Nakayama T; Harasawa H; Tago H; Izawa D; Hieshima K; Tatsumi Y; Matsushima K; Hasegawa H; Kanamaru A; Kamihira S; Yamada Y
Blood; 2002 Mar; 99(5):1505-11. PubMed ID: 11861261
[TBL] [Abstract][Full Text] [Related]
15. CCR4 and its ligands: from bench to bedside.
Yoshie O; Matsushima K
Int Immunol; 2015 Jan; 27(1):11-20. PubMed ID: 25087232
[TBL] [Abstract][Full Text] [Related]
16. The chemokine receptor CCR4 in vascular recognition by cutaneous but not intestinal memory T cells.
Campbell JJ; Haraldsen G; Pan J; Rottman J; Qin S; Ponath P; Andrew DP; Warnke R; Ruffing N; Kassam N; Wu L; Butcher EC
Nature; 1999 Aug; 400(6746):776-80. PubMed ID: 10466728
[TBL] [Abstract][Full Text] [Related]
17. Defucosylated anti CC chemokine receptor 4 monoclonal antibody combined with immunomodulatory cytokines: a novel immunotherapy for aggressive/refractory Mycosis fungoides and Sezary syndrome.
Yano H; Ishida T; Inagaki A; Ishii T; Ding J; Kusumoto S; Komatsu H; Iida S; Inagaki H; Ueda R
Clin Cancer Res; 2007 Nov; 13(21):6494-500. PubMed ID: 17975162
[TBL] [Abstract][Full Text] [Related]
18. Humanization of an anti-CCR4 antibody that kills cutaneous T-cell lymphoma cells and abrogates suppression by T-regulatory cells.
Chang DK; Sui J; Geng S; Muvaffak A; Bai M; Fuhlbrigge RC; Lo A; Yammanuru A; Hubbard L; Sheehan J; Campbell JJ; Zhu Q; Kupper TS; Marasco WA
Mol Cancer Ther; 2012 Nov; 11(11):2451-61. PubMed ID: 22869555
[TBL] [Abstract][Full Text] [Related]
19. Specific recruitment of CC chemokine receptor 4-positive regulatory T cells in Hodgkin lymphoma fosters immune privilege.
Ishida T; Ishii T; Inagaki A; Yano H; Komatsu H; Iida S; Inagaki H; Ueda R
Cancer Res; 2006 Jun; 66(11):5716-22. PubMed ID: 16740709
[TBL] [Abstract][Full Text] [Related]
20. Anti-CCR4 mAb selectively depletes effector-type FoxP3+CD4+ regulatory T cells, evoking antitumor immune responses in humans.
Sugiyama D; Nishikawa H; Maeda Y; Nishioka M; Tanemura A; Katayama I; Ezoe S; Kanakura Y; Sato E; Fukumori Y; Karbach J; Jäger E; Sakaguchi S
Proc Natl Acad Sci U S A; 2013 Oct; 110(44):17945-50. PubMed ID: 24127572
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
